DB2313 NEW

Price	$50	$122	$197
Package	1mg	5mg	10mg

Min. Order:
Supply Ability:	10g
Update Time:	2025-07-05

Product Details

Product Name: DB2313	CAS No.: 2170606-74-1
Purity: 99.73%	Supply Ability: 10g
Release date: 2025/07/05

Product Introduction

Bioactivity

Name	DB2313
Description	DB2313 (Carboximidamide) is a potent transcription factor PU.1 inhibitor, IC50=14 nM. DB2313 disrupts the interaction of PU.1 with target gene promoters. DB2313 induces apoptosis of acute myeloid leukemia (AML) cells, and has anticancer effects
In vitro	DB2313 reduces PU.1 binding to the promoters of E2f1, Junb, and Csf1r in acute myeloid leukemia (AML) cells, significantly impairing their proliferation, particularly in PU.1 URE–/– AML cells where it shows an IC50 of 7.1 μM with minimal impact on normal hematopoietic cells at comparable doses. This treatment also increases apoptosis by 3.5 times in PU.1 URE–/– AML murine cells and notably diminishes their clonogenic survival across successive replatings, culminating in a total loss of clonogenic capacity from the fourth replating onwards[1].
In vivo	DB2313 (17 mg/kg; i.p.; three times per week for 3 weeks) treatment reduces leukemia progression and enhances survival in mice.
Storage	store at low temperature \| Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
Solubility Information	DMSO : 3 mg/mL (4.2 mM), Sonication and heating to 70℃ are recommended.
Keywords	DB-2313 \| DB2313 \| DB 2313 \| Apoptosis
Inhibitors Related	Stavudine \| 5-Fluorouracil \| Flubendazole \| Cysteamine hydrochloride \| Myricetin \| Dextran sulfate sodium salt (MW 4500-5500) \| Sodium 4-phenylbutyrate \| L-Ascorbic acid \| L-Glutamic acid \| Tributyrin \| L-Ascorbic acid sodium salt \| Alginic acid
Related Compound Libraries	Apoptosis Compound Library \| Bioactive Compound Library \| Hematonosis Compound Library \| Inhibitor Library \| Bioactive Compounds Library Max \| Fluorochemical Library \| Anti-Cancer Compound Library \| Anti-Cancer Active Compound Library \| Transcription Factor-Targeted Compound Library

Company Profile Introduction

Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers. TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.